GoldenGolden
Advanced Search
BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics

A biotechnology company that develops stem cell therapies for the treatment of neurodegenerative diseases

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

July 27, 2012
BrainStorm Cell Therapeutics raises a $206,910 seed round.

Funding rounds

People

Name
Role
LinkedIn

Adrian Harel

Employee

Liat Soffer

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

BrainStorm Cell Therapeutics

April 27, 2018

BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study

January 11, 2019

Brainstorm Cell Therapeutics updates on its progressive MS drug development trials

February 12, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Brainstorm Cell Therapeutics Inc
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Heather McKenzie
May 4, 2021
BioSpace
There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve.
Brainstorm Cell Therapeutics Inc
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...
Nick Paul
March 24, 2021
FierceBiotech
BrainStorm Cell Therapeutics has presented phase 2 data on its stem cell therapy in patients with multiple sclerosis. The small, open-label clinical trial linked autologous therapy NurOwn to a 25% improvement in measures of mobility and dexterity in around 14% of patients.
Pomerantz LLP
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
Pomerantz LLP
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
Brandon May
November 17, 2020
BioSpace
A Phase III trial of NurOwn® (MSC-NTF cells), BrainStorm Cell Therapeutics' investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the therapy and placebo for improving scores on a revised ALS functional rating scale.
Brian Barrett
June 23, 2020
Wired
At 37, Brian Wallach was diagnosed with the fatal disease. So he tapped a lifetime of connections to give help and hope to fellow sufferers--while grappling with his own mortality.
BioSpace
June 9, 2020
BioSpace
The ALS Association and I AM ALS announced that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics, a biotechnology company, to support an amyotrophic lateral sclerosis biomarker research study.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.